US20100081788A1 - Process for the Preparation of Pramlintide - Google Patents
Process for the Preparation of Pramlintide Download PDFInfo
- Publication number
- US20100081788A1 US20100081788A1 US12/553,567 US55356709A US2010081788A1 US 20100081788 A1 US20100081788 A1 US 20100081788A1 US 55356709 A US55356709 A US 55356709A US 2010081788 A1 US2010081788 A1 US 2010081788A1
- Authority
- US
- United States
- Prior art keywords
- asn
- tbu
- trt
- thr
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Definitions
- the present invention relates to the efficient commercial synthesis for the making of pramilintide, a synthetic analog of human amylin which is a peptide hormone.
- Pramilintide is indicated to treat type 1 and type 2 diabetics who use insulin.
- the process for making pramilintide substantially comprises the syntheses of various fragments of the polypeptide and the coupling of the fragments to produce pramilintide.
- pramlintide is disclosed in U.S. Pat. No. 5,686,411, which is herein incorporated in its entirety by reference.
- Pramlintide is known to be prepared by solid phase synthesis that successively adds the desired amino acid to a growing peptide chain.
- an ⁇ -N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin support are reacted at room temperature in an inert solvent in the presence of coupling agents such as dicyclohexylcarbodiimide 1-hydroxybenzotriazole in the presence of a base.
- the ⁇ -N-carbamoyl protecting group is removed from the resultant peptide with a reagent such as trifluoroacetic acid or piperidine, and the coupling reaction repeated with the next desired N-protected amino acid.
- a reagent such as trifluoroacetic acid or piperidine
- Suitable N-protecting groups are known in the art, with t-butyloxycarbonyl herein preferred.
- U.S. Pat. No. 5,424,394 provides a classical stepwise approach for the synthesis of amylin and amylin analogues. Single amino acid residues are covalently coupled to a growing peptide chain which is covalently linked to a solid resin support. The synthetic route is very lengthy and inefficiently since several coupling and deprotected steps have to be repeated.
- the present invention provides a more efficient synthesis of pramlintide and the yield and purity of final product will be improved in view of the prior art.
- the present invention provides for an efficient process for making pramlinitide that is high in yield and scalable for commercial production.
- the process comprises the stepwise synthesis of amino acid segments, and the coupling together of these segments to produce pramlinitide.
- the present invention provides for four novel intermediate amino acid segments for the preparation of pramlintide.
- the four segments are synthesized in solid phase synthesis and the coupling reaction is performed in solution phase.
- the segments are produced by coupling a protected designated amino acid to a growing peptide chain that is covalently linked to an insoluble solid resin support.
- the “protected designated amino acid” refers to single amino acid (having protected sidechains and amino termini) which generally proceed from the carboxy-terminal end to the amino-terminal end to give a peptide of specified sequence.
- a “growing peptide chain” refers to a general cycle of synthesis comprising deprotection of the ⁇ -amino group of the resin-bound amino acid or peptide, followed by reaction (coupling) of the free ⁇ -amino group with some carboxyl-activated form of the next ⁇ -amino protected amino acid to form a peptide linkage and to give a support-bound peptide.
- the Fmoc protecting group was removed by treatment with 20% piperidine in DMF twice for 10 min and 30 min, respectively.
- the second amino acid (Fmoc-Cys (Acm)-OH) was introduced to start the first coupling step.
- the Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU (O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate)/HOBt (N-Hydroxybenzotriazole)/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h.
- the peptide was cleaved from the peptide on resin (8 g) prepared as described above, using 20% TFE solution in DCM for 2 h.
- the peptide solution was solvent replaced by MeOH and concentrated (30 mL).
- the concentrated residue was cooled and the product was precipitated by adding water (30 mL).
- the precipitated product was separated by filtration and washed with mixed solvent of MeOH/water (10 mL/10 mL) twice to give Boc-Lys(Boc)-Cys(Acm)-Asn(Trt)-Thr(tBu)-Ala-Thr(tBu)-Cys(Acm)-Ala-OH(S1a).
- the second amino acid (Fmoc-His(Trt)-OH) was introduced to start the first coupling step.
- the Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU/HOBt/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h. Completion of the coupling was indicated by a Kaiser test.
- the Fmoc protecting group on the ⁇ -amine was removed with 20% piperidine in DMF twice for 10 min and 30 min, respectively. These steps were repeated each time with another amino acid according to peptide sequence. All amino acids used were Fmoc-N ⁇ protected.
- Trifunctional amino acids were side chain protected as follows: Asn(Trt)-OH, Arg(Pbf)-OH, Gln(Trt)-OH and Thr(tBu)-OH. Three equivalents of the activated amino acids were employed in the coupling reactions. At the end of the synthesis the growing peptide on resin was washed with DMF, MeOH followed by MTBE, and dried under vacuum to give dry peptide on resin.
- the peptide was cleaved from the peptide on resin (24 g) prepared as described above, using 20% TFE solution in DCM for 2 h.
- the peptide solution was solvent replaced by MeOH and concentrated (50 mL).
- the product was absolutely precipitated by adding cool MeOH (50 mL) to the concentrated residue.
- the product was separated by filtration and washed with cool MeOH (20 mL) twice to give S2 (Fmoc-Thr(tBu)-Gln(Trt)-Arg(Pbf)-Leu-Ala-Asn(Trt)-Phe-Leu-Val-His(Trt)-Ser(tBu)-O H, 12 g).
- the Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU/HOBt/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h. Completion of the coupling was indicated by a Kaiser test. After washing of the resin, the Fmoc protecting group on the ⁇ -amine was removed with 20% piperidine in DMF twice for 10 min and 30 min, respectively. These steps were repeated each time with another amino acid according to peptide sequence. All amino acids used were Fmoc-N ⁇ protected. Trifunctional amino acids were side chain protected as follows: Ser(tBu)-OH, and Asn(Trt)-OH. Three equivalents of the activated amino acids were employed in the coupling reactions. At the end of the synthesis the growing peptide on resin was washed with DMF, MeOH followed by MTBE, and dried under vacuum to give dry peptide on resin.
- the peptide was cleaved from the growing peptide on resin (10 g) prepared as described above, using 1% TFA solution in DCM for 1.5 h. After neutralizing with Pyridine the peptide solution was concentrated (15 mL). The product was precipitated by adding the concentrated residue into Heptanes (50 mL). The product was separated by filtration and washed with mixed solvent of DCM/Heptanes (1 mL/3 mL) three times to give S3 (Fmoc-Ser(tBu)-Asn(Trt)-Asn(Trt)-Phe-Gly-Pro-Ile-Leu-Pro-Pro-OH, 5.2 g).
- the second amino acid (Fmoc-Asn(Trt)-OH) was introduced to start the first coupling step.
- the Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU/HOBt/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h. Completion of the coupling was indicated by a Kaiser test.
- the Fmoc protecting group on the ⁇ -amine was removed with 20% piperidine in DMF twice for 10 min and 30 min, respectively. These steps were repeated each time with another amino acid according to peptide sequence. All amino acids used were Fmoc-N ⁇ protected.
- Trifunctional amino acids were side chain protected as follows: Ser(tBu)-OH, Asn(Trt)-OH and Thr(tBu)-OH. Three equivalents of the activated amino acids were employed in the coupling reactions. At the end of the synthesis the growing peptide on resin was washed with DMF, MeOH followed by MTBE, and dried under vacuum to give dry peptide on resin.
- the peptide was cleaved from the peptide on resin (23 g) prepared as described above, using 20% TFE solution in DCM for 2 h.
- the peptide solution was solvent replaced by MeOH and concentrated (60 mL).
- the product was precipitated by adding MeOH (50 mL) to the concentrated residue.
- the product was separated by filtration and washed with MeOH/water (20 mL) twice to give S4 (Fmoc-Thr(tBu)-Asn(Trt)-Val-Gly-Ser(tBu)-Asn(Trt)-Thr(tBu)-OH, 10.6 g)
- the reaction mixture is warmed to 20 to 30° C. and kept for 15 hr. Diethylamine (DEA) (0.42 Kg; 10.0 eq.) is charged while maintaining the temperature at 25° C.
- DEA Diethylamine
- the reaction mixture is stirred at 20 to 30° C. for 2 hr.
- Ethyl acetate (EA) (7.38 Kg) and softened potable water (SPW) (50.0 Kg) are slowly added to the reaction mixture while maintaining the temperature at 35° C. until the cloud point is observed and held at cloud point for 1 hr. The remained SPW is added while maintaining the temperature at 35° C.
- the wet cake is purged by nitrogen for 1 hr and dried at 50° C. for 5 hr to get M2 (Thr(tBu)Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr(tBu) Tyr(tBu)-NH 2 ) (about 0.81 Kg).
- Ethyl(3-dimethylaminopropyl)carbodiimide hydrochloride (0.30 Kg; 3.0 eq) is charged into the resulting mixture while maintaining the temperature at 20 to 30° C. and stirred for 3 hr.
- Ethyl acetate (EA) (5.1 Kg) and SPW (43.6 Kg) are slowly added into the reaction mixture while maintaining the temperature at 35° C. until the cloud point is observed and held at cloud point for 1 hr. The remained SPW is added while maintaining the temperature at 35° C.
- the solid is filtered and washed by MeOH twice. The wet cake is purged with nitrogen for 1 hr and dried at 50° C.
- the wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 5 hr to provide M4 (Ser(tBu)Asn(Trt)Asn(Trt)PheGlyProlleLeuProProThr(tBu)Asn(Trt)ValGlySer(tBu) Asn(Trt)Thr(tBu)Tyr(tBu)-NH 2 ) (about 1.32 Kg).
- M5 (2.16 Kg; 1.0 eq) and dichloromethane (DCM) (28.7 Kg) are charged into a suitable reactor under nitrogen. Then piperidine (0.32 Kg; 10.0 eq) is charged while maintaining the temperature at 20 to 30° C. and stirred for 2 hr. Methyl-t-butyl ether (MTBE) (47.9 Kg) is slowly added while maintaining the temperature at 0 to 10° C. until the cloud point is observed and held at cloud point for 1 hr. The remained MTBE is added while maintaining the temperature at 0 to 10° C.
- MTBE Methyl-t-butyl ether
- the wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 5 hr to provide M6 (Thr(tBu)Gln(Trt)Arg(Pbf)LeuAlaAsn(Trt)Phe LeuValHis(Trt)Ser(tBu)Ser(tBu)Asn(Trt)Asn(Trt)PheGlyProlleLeuProProThr(tBu) Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr(tBu)Tyr(tBu)-NH 2 ) (about 1.87 Kg).
- 1-hydroxy-7-azabenzotriazole (0.14 Kg; 3.0 eq.) are charged into a suitable reactor under nitrogen.
- M7 (2.09 Kg) is charged into reactor I under nitrogen.
- the solid is kept at temperature 0 to 10° C.
- SPW 0.52 Kg
- TEA trifluoroacetic acid
- TIS triisopropylsilane
- the mixed solution in reactor II is cooled to 0 to 10° C. and charged into reactor I at 25° C.
- the reaction mixture is stirred at 20-30° C. for 3 hr.
- the reaction mixture is cooled to 0 to 10° C. and the pre-cooled (0 to 10° C.) methyl-t-butyl ether (MTBE) (61.85 Kg) is slowly charged at 15° C. and stirred for 1 hr.
- the solid product is filtered and washed with methyl-t-butylether (MTBE) twice and tetrahydrofuran (THF) twice.
- the wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 6 hr to provide pramlintide acetate (about 1.21 Kg).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Analytical Chemistry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention provides for an efficient process for making Pramlinitide, as well as novel intermediates for the making of the same.
Description
- This application claims priority from U.S. Provisional Patent Application Ser. No. 61/190,928 which was filed on Sep. 3, 2008. The entire content of which is herein incorporated by reference.
- 1. Field of the Invention
- The present invention relates to the efficient commercial synthesis for the making of pramilintide, a synthetic analog of human amylin which is a peptide hormone. Pramilintide is indicated to treat type 1 and type 2 diabetics who use insulin. The process for making pramilintide substantially comprises the syntheses of various fragments of the polypeptide and the coupling of the fragments to produce pramilintide.
- 2. Description of the Related Arts
- The preparation and use of pramlintide is disclosed in U.S. Pat. No. 5,686,411, which is herein incorporated in its entirety by reference. Pramlintide is known to be prepared by solid phase synthesis that successively adds the desired amino acid to a growing peptide chain. Typically, an α-N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin support are reacted at room temperature in an inert solvent in the presence of coupling agents such as dicyclohexylcarbodiimide 1-hydroxybenzotriazole in the presence of a base. The α-N-carbamoyl protecting group is removed from the resultant peptide with a reagent such as trifluoroacetic acid or piperidine, and the coupling reaction repeated with the next desired N-protected amino acid. Suitable N-protecting groups are known in the art, with t-butyloxycarbonyl herein preferred. U.S. Pat. No. 5,424,394 provides a classical stepwise approach for the synthesis of amylin and amylin analogues. Single amino acid residues are covalently coupled to a growing peptide chain which is covalently linked to a solid resin support. The synthetic route is very lengthy and inefficiently since several coupling and deprotected steps have to be repeated. The present invention provides a more efficient synthesis of pramlintide and the yield and purity of final product will be improved in view of the prior art.
- The present invention provides for an efficient process for making pramlinitide that is high in yield and scalable for commercial production. The process comprises the stepwise synthesis of amino acid segments, and the coupling together of these segments to produce pramlinitide. The present invention provides for four novel intermediate amino acid segments for the preparation of pramlintide. In a preferable embodiment of the invention, the four segments are synthesized in solid phase synthesis and the coupling reaction is performed in solution phase. Preferably, the segments are produced by coupling a protected designated amino acid to a growing peptide chain that is covalently linked to an insoluble solid resin support. The “protected designated amino acid” refers to single amino acid (having protected sidechains and amino termini) which generally proceed from the carboxy-terminal end to the amino-terminal end to give a peptide of specified sequence. A “growing peptide chain” refers to a general cycle of synthesis comprising deprotection of the α-amino group of the resin-bound amino acid or peptide, followed by reaction (coupling) of the free α-amino group with some carboxyl-activated form of the next α-amino protected amino acid to form a peptide linkage and to give a support-bound peptide.
- To assist in understanding the present invention, the following examples are included which describe the results of a series of experiments. The following examples relating to this invention should not, of course, be construed as specifically limiting the invention. Such variations of the invention, now known or later developed, which would be within the purview of one skilled in the art are considered to fall within the scope of the present invention as hereinafter claimed.
-
- Synthesis of the protected peptide was carried out by a stepwise Fmoc SPPS (solid phase peptide synthesis) procedure starting with loading a Fmoc-Ala-OH to 2-Cl-Trt-Cl resin (CTC resin). The CTC resin (4 g) after washing was stirred with a solution of Fmoc-Ala-OH (1.49 g) in DMF in the presence of diisopropylethylamine (DIEA, 2.3 g) for 1.5 h. The resin was further capped by treatment with mixed solvent of 5:4:1 volume ratio of DCM/MeOH/DIEA for 0.5 h. After washing of the resin the Fmoc protecting group was removed by treatment with 20% piperidine in DMF twice for 10 min and 30 min, respectively. After washing of residual reagents the second amino acid (Fmoc-Cys (Acm)-OH) was introduced to start the first coupling step. The Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU (O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate)/HOBt (N-Hydroxybenzotriazole)/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h. Completion of the coupling was indicated by a Kaiser test. After washing of the resin, the Fmoc protecting group on the α-amine was removed with 20% piperidine in DMF twice for 10 min and 30 min, respectively. These steps were repeated each time with another amino acid according to peptide sequence. All amino acids used were Fmoc-Nα protected except the last amino acid in the sequence, Boc-Lys(Boc)-OH. Trifunctional amino acids were side chain protected as follows: Lys(Boc)-OH, Asn(Trt)-OH, Thr(tBu)-OH. Three equivalents of the activated amino acids were employed in the coupling reactions. At the end of the synthesis the peptide resin was washed with DMF, MeOH followed by MTBE, and dried under vacuum to give dry peptide on resin.
- The peptide was cleaved from the peptide on resin (8 g) prepared as described above, using 20% TFE solution in DCM for 2 h. The peptide solution was solvent replaced by MeOH and concentrated (30 mL). The concentrated residue was cooled and the product was precipitated by adding water (30 mL). The precipitated product was separated by filtration and washed with mixed solvent of MeOH/water (10 mL/10 mL) twice to give Boc-Lys(Boc)-Cys(Acm)-Asn(Trt)-Thr(tBu)-Ala-Thr(tBu)-Cys(Acm)-Ala-OH(S1a).
- 10 g S1a was dissolved in a mixed solvent of DMF/pyridine/MeOH, and then add a solution with I2 in DMF/MeOH during 2.5 h. After 1 h, the mixture was quenched with Vitamin C/ammonium acetate in water. More water was added to gain crude S1. Further purification was carried out by silica gel to give S1
- Synthesis of the protected peptide was carried out by a stepwise Fmoc SPPS (solid phase peptide synthesis) procedure starting with loading a Fmoc-Ser(tBu)-OH to 2-Cl-Trt-Cl resin (CTC resin). The CTC resin (10 g) after washing was stirred with a solution of Fmoc-Ser(tBu)-OH (4.6 g) in DMF in the presence of diisopropylethylamine (2.3 g) for 1.5 h. After washing of the resin the Fmoc protecting group was removed by treatment with 20% piperidine in DMF twice for 10 min and 30 min, respectively. After washing of residual reagents the second amino acid (Fmoc-His(Trt)-OH) was introduced to start the first coupling step. The Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU/HOBt/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h. Completion of the coupling was indicated by a Kaiser test. After washing of the resin, the Fmoc protecting group on the α-amine was removed with 20% piperidine in DMF twice for 10 min and 30 min, respectively. These steps were repeated each time with another amino acid according to peptide sequence. All amino acids used were Fmoc-Nα protected. Trifunctional amino acids were side chain protected as follows: Asn(Trt)-OH, Arg(Pbf)-OH, Gln(Trt)-OH and Thr(tBu)-OH. Three equivalents of the activated amino acids were employed in the coupling reactions. At the end of the synthesis the growing peptide on resin was washed with DMF, MeOH followed by MTBE, and dried under vacuum to give dry peptide on resin.
- The peptide was cleaved from the peptide on resin (24 g) prepared as described above, using 20% TFE solution in DCM for 2 h. The peptide solution was solvent replaced by MeOH and concentrated (50 mL). The product was absolutely precipitated by adding cool MeOH (50 mL) to the concentrated residue. The product was separated by filtration and washed with cool MeOH (20 mL) twice to give S2 (Fmoc-Thr(tBu)-Gln(Trt)-Arg(Pbf)-Leu-Ala-Asn(Trt)-Phe-Leu-Val-His(Trt)-Ser(tBu)-O H, 12 g).
- Synthesis of the protected peptide was carried out by a stepwise Fmoc SPPS (solid phase peptide synthesis) procedure starting with loading a Fmoc-Pro-OH to 2-Cl-Trt-Cl resin (CTC resin). The CTC resin (3 g) after washing was stirred with a solution of Fmoc-Pro-OH (1.2 g) in DMF in the presence of diisopropylethylamine (2.3 g) for 1.5 h. After washing of the resin the Fmoc protecting group was removed by treatment with 20% piperidine in DMF twice for 10 min and 30 min, respectively. After washing of residual reagents the second amino acid (Fmoc-Pro-OH) was introduced to start the first coupling step. The Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU/HOBt/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h. Completion of the coupling was indicated by a Kaiser test. After washing of the resin, the Fmoc protecting group on the α-amine was removed with 20% piperidine in DMF twice for 10 min and 30 min, respectively. These steps were repeated each time with another amino acid according to peptide sequence. All amino acids used were Fmoc-Nα protected. Trifunctional amino acids were side chain protected as follows: Ser(tBu)-OH, and Asn(Trt)-OH. Three equivalents of the activated amino acids were employed in the coupling reactions. At the end of the synthesis the growing peptide on resin was washed with DMF, MeOH followed by MTBE, and dried under vacuum to give dry peptide on resin.
- The peptide was cleaved from the growing peptide on resin (10 g) prepared as described above, using 1% TFA solution in DCM for 1.5 h. After neutralizing with Pyridine the peptide solution was concentrated (15 mL). The product was precipitated by adding the concentrated residue into Heptanes (50 mL). The product was separated by filtration and washed with mixed solvent of DCM/Heptanes (1 mL/3 mL) three times to give S3 (Fmoc-Ser(tBu)-Asn(Trt)-Asn(Trt)-Phe-Gly-Pro-Ile-Leu-Pro-Pro-OH, 5.2 g).
- Synthesis of the protected peptide was carried out by a stepwise Fmoc SPPS (solid phase peptide synthesis) procedure starting with loading a Fmoc-Thr(tBu)-OH to 2-Cl-Trt-Cl resin (CTC resin). The CTC resin (10 g) after washing was stirred with a solution of Fmoc-Thr(tBu)-OH (4.8 g) in DMF in the presence of diisopropylethylamine (2.3 g) for 1.5 h. After washing of the resin the Fmoc protecting group was removed by treatment with 20% piperidine in DMF twice for 10 min and 30 min, respectively. After washing of residual reagents the second amino acid (Fmoc-Asn(Trt)-OH) was introduced to start the first coupling step. The Fmoc protected amino acid was activated in situ using 1:1:2 molar ratio of HBTU/HOBt/DIEA in DMF and subsequently coupled to the growing peptide on resin for 3 h. Completion of the coupling was indicated by a Kaiser test. After washing of the resin, the Fmoc protecting group on the α-amine was removed with 20% piperidine in DMF twice for 10 min and 30 min, respectively. These steps were repeated each time with another amino acid according to peptide sequence. All amino acids used were Fmoc-Nα protected. Trifunctional amino acids were side chain protected as follows: Ser(tBu)-OH, Asn(Trt)-OH and Thr(tBu)-OH. Three equivalents of the activated amino acids were employed in the coupling reactions. At the end of the synthesis the growing peptide on resin was washed with DMF, MeOH followed by MTBE, and dried under vacuum to give dry peptide on resin.
- The peptide was cleaved from the peptide on resin (23 g) prepared as described above, using 20% TFE solution in DCM for 2 h. The peptide solution was solvent replaced by MeOH and concentrated (60 mL). The product was precipitated by adding MeOH (50 mL) to the concentrated residue. The product was separated by filtration and washed with MeOH/water (20 mL) twice to give S4 (Fmoc-Thr(tBu)-Asn(Trt)-Val-Gly-Ser(tBu)-Asn(Trt)-Thr(tBu)-OH, 10.6 g)
- S4 (FmocThr(tBu)Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr(tBu)OH) (1.0 kg; 1.0 Eq.), H-Tyr(tBu)-NH2 (0.45 Kg; 3.0 eq.) and 1-hydroxy-7-azabenzotriazole (HOAt) (0.26 Kg; 3.0 eq) are charged into a suitable reactor under nitrogen. 1-methyl-2-pyrrolidinone (NMP) (20.7 Kg) is charged and stirred for 0.5 hr. The resulting mixture is cooled to 0 to 10° C. Then the solution of N,N-diisopropylcarbodiimide (DIC) (0.24 Kg; 3.0 eq) and 1-methyl-2-pyrrolidinone (NMP) (10.3 Kg) is dropped into the cooled resulting mixture for 1 hr while maintaining the temperature at 0 to 10° C.
- The reaction mixture is warmed to 20 to 30° C. and kept for 15 hr. Diethylamine (DEA) (0.42 Kg; 10.0 eq.) is charged while maintaining the temperature at 25° C. The reaction mixture is stirred at 20 to 30° C. for 2 hr. Ethyl acetate (EA) (7.38 Kg) and softened potable water (SPW) (50.0 Kg) are slowly added to the reaction mixture while maintaining the temperature at 35° C. until the cloud point is observed and held at cloud point for 1 hr. The remained SPW is added while maintaining the temperature at 35° C. The solid is filtered and washed with mixed solvent MeOH/SPW=1/1 twice and n-heptane twice. The wet cake is purged by nitrogen for 1 hr and dried at 50° C. for 5 hr to get M2 (Thr(tBu)Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr(tBu) Tyr(tBu)-NH2) (about 0.81 Kg).
- M2 (0.81 Kg; 1.0 eq), S3 (Fmoc-Ser(tBu)Asn(Trt)Asn(Trt)PheGlyProlleLeu ProProOH) (0.85 Kg; 0.9 eq) and 1-hydroxy-7-azabenzotriazole (HOAt) (0.21 Kg; 3.0 eq) are charged into a suitable reactor under nitrogen. Then 1-methyl-2-pyrrolidinone (NMP) (16.7 Kg) is charged and stirred for 0.5 hr. The resulting mixture is cooled to 0 to 10° C.
- Ethyl(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (0.30 Kg; 3.0 eq) is charged into the resulting mixture while maintaining the temperature at 20 to 30° C. and stirred for 3 hr. Ethyl acetate (EA) (5.1 Kg) and SPW (43.6 Kg) are slowly added into the reaction mixture while maintaining the temperature at 35° C. until the cloud point is observed and held at cloud point for 1 hr. The remained SPW is added while maintaining the temperature at 35° C. The solid is filtered and washed by MeOH twice. The wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 5 hr to get M3 (FmocSer(tBu)Asn(Trt)Asn(Trt)PheGlyProlleLeuProProThr(tBu)Asn(Trt)ValGly Ser(tBu)Asn(Trt)Thr(tBu)Tyr(tBu)-NH2) (about 1.56 Kg).
- M3 (1.56 Kg; 1.0 eq) and dichloromethane (DCM) (12.5 Kg) are charged into a suitable reactor. Then piperidine (0.60 Kg; 15.0 eq) is charged while maintaining the temperature at 20 to 30° C. and stirred for 2 hr. Methyl-t-butyl ether (MTBE) (34.7 Kg) is slowly added while maintaining the temperature at 30° C. until the cloud point is observed and held at cloud point for 1 hr. The remained MTBE is added while maintaining the temperature at 30° C. The product is filtered and washed with mixed solvent of MeOH/SPW=1/1 twice and methyl-t-butyl ether (MTBE) twice. The wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 5 hr to provide M4 (Ser(tBu)Asn(Trt)Asn(Trt)PheGlyProlleLeuProProThr(tBu)Asn(Trt)ValGlySer(tBu) Asn(Trt)Thr(tBu)Tyr(tBu)-NH2) (about 1.32 Kg).
- M4 (1.32 Kg; 1.0 eq), S2 (FmocThr(tBu)Gln(Trt)Arg(Pbf)LeuAlaAsn(Trt) PheLeuValHis(Trt)Ser(tBu)OH) (1.03 Kg; 0.95 eq) and 1-hydroxy-7-azabenzotriazole (HOAt) (0.17 Kg; 3.0 eq) are charged into a suitable reactor under nitrogen. Then 1-methyl-2-pyrrolidinone (NMP) (27.17 Kg) is charged and stirred for 0.5 hr. The resulting mixture is cooled to 0 to 10° C.
- The solution of N,N-diisopropylcarbodiimide (DIC) (0.16 Kg; 3.0 eq) and 1-methyl-2-pyrrolidinone (NMP) (6.80 Kg) is dropped to the cooled resulting mixture for 1 hr while maintaining the temperature at 0 to 10° C. The reaction mixture is warmed to 20 to 30° C. and kept for 15 hr. Ethyl acetate (EA) (9.47 Kg) is charged into the reaction mixture. Mixed solvent of MeOH/SPW=1/1 (86.8 Kg) is slowly added while maintaining the temperature at 35° C. until the cloud point is observed and held at cloud point for 1 hr. The remained SPW is added while maintaining the temperature at 35° C. The solid is filtered and washed by mixed solvent of MeOH/SPW=4/1. The wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 5 hr to provide M5 (FmocThr(tBu)Gln(Trt)Arg(Pbf)LeuAlaAsn(Trt)PheLeuValHis(Trt)Ser(tBu) Ser(tBu)Asn(Trt)Asn(Trt)PheGlyProlleLeuProProThr(tBu)Asn(Trt)ValGly Ser(tBu)Asn(Trt)Thr(tBu)Tyr(tBu)-NH2) (about 2.16 Kg)
- M5 (2.16 Kg; 1.0 eq) and dichloromethane (DCM) (28.7 Kg) are charged into a suitable reactor under nitrogen. Then piperidine (0.32 Kg; 10.0 eq) is charged while maintaining the temperature at 20 to 30° C. and stirred for 2 hr. Methyl-t-butyl ether (MTBE) (47.9 Kg) is slowly added while maintaining the temperature at 0 to 10° C. until the cloud point is observed and held at cloud point for 1 hr. The remained MTBE is added while maintaining the temperature at 0 to 10° C. The product is filtered and washed with mixed solvent of MeOH/SPW=4/1 twice and methyl-t-butyl ether (MTBE) twice. The wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 5 hr to provide M6 (Thr(tBu)Gln(Trt)Arg(Pbf)LeuAlaAsn(Trt)Phe LeuValHis(Trt)Ser(tBu)Ser(tBu)Asn(Trt)Asn(Trt)PheGlyProlleLeuProProThr(tBu) Asn(Trt)ValGlySer(tBu)Asn(Trt)Thr(tBu)Tyr(tBu)-NH2) (about 1.87 Kg).
- M6 (1.87 Kg; 1.0 eq.), S1
- and 1-hydroxy-7-azabenzotriazole (HOAt) (0.14 Kg; 3.0 eq.) are charged into a suitable reactor under nitrogen. 1-Methyl-2-pyrrolidinone (NMP) (19.3 Kg) is charged and stirred for 0.5 hr. The resulting mixture is cooled to 0 to 10° C.
- The solution of N,N-diisopropylcarbodiimide (DIC) (0.13 Kg; 3.0 eq.) and 1-methyl-2-pyrrolidinone (NMP) (9.63 Kg) is dropped to the cooled resulting mixture for 1 hr while maintaining the temperature at 0 to 10° C. The reaction mixture is kept at 0 to 10° C. for 0.5 hr, followed by warmed to 20 to 30° C. and stirred for 17 hr. Ethyl acetate (EA) (8.39 Kg) is charged into the reaction mixture. SPW (74.6 Kg) is slowly added while maintaining the temperature at 35° C. until the cloud point is observed and held at cloud point for 1 hr. The remained SPW is added while maintaining the temperature at 35° C. for 2 hr. The solid is filtered and washed with mixed solvent of MeOH/SPW=4/1 three times.
- The wet cake is purged with nitrogen for 1 hr and dried at 30° C. to get M7 (Boc-S1S2S3S4Try(tBu)NH2) (about 2.09 Kg).
- M7 (2.09 Kg) is charged into reactor I under nitrogen. The solid is kept at temperature 0 to 10° C. SPW (0.52 Kg), trifluoroacetic acid (TEA) (29.38 Kg), and triisopropylsilane (TIS) (0.47 Kg) are charged into reactor II under nitrogen.
- The mixed solution in reactor II is cooled to 0 to 10° C. and charged into reactor I at 25° C. The reaction mixture is stirred at 20-30° C. for 3 hr.
- The reaction mixture is cooled to 0 to 10° C. and the pre-cooled (0 to 10° C.) methyl-t-butyl ether (MTBE) (61.85 Kg) is slowly charged at 15° C. and stirred for 1 hr. The solid product is filtered and washed with methyl-t-butylether (MTBE) twice and tetrahydrofuran (THF) twice. The wet cake is purged with nitrogen for 1 hr and dried at 50° C. for 6 hr to provide pramlintide acetate (about 1.21 Kg).
Claims (20)
1. A process for the preparation of pramlintide of formula (I):
wherein P1 and P2 are protecting groups, with H-Tyr(P2)-NH2 to yield a protected side chain peptide of formula (III)
(b) removing the terminal P1 protecting group and reacting with a protecting side chain peptide of formula (IV)
wherein P1 and P2 are as defined above, to yield a protected side chain peptide of formula (V)
(c) removing the terminal P protecting group and reacting with a protecting side chain peptide of formula (VI)
wherein P1 and P2 are as defined above, to yield a protected side chain peptide of formula (VII)
(d) removing the terminal P protecting group and reacting a protecting side chain peptide of formula (VIII)
2. The process of claim 1 , wherein P1 is Fmoc or Boc.
3. The process of claim 1 , wherein P1 in step (d) is Boc.
4. The process of claim 1 , wherein P2 is selected from tBu, Trt and Pbf
5. The process of claim 1 , wherein steps (a) to (e) are performed in solution.
6. The process of claim 1 , wherein at least one of the coupling reaction of steps a) to d) is accomplished with the reagent selected from 1-hydroxy-7-azabenzotriazole, 1-methyl-2-pyrrolidinone, ethyl(3-dimethylaminopropyl)carbodiimide hydrochloride, N,N-diisopropylcarbodiimide and combinations thereof.
7. The process of claim 1 , wherein the deprotecting step is carried out with piperidine when the protecting group is Fmoc or with trifluoroacetic acid when the protecting group is Boc.
8. A protected side chain peptide of formula (III)
wherein P1 and P2 are protecting groups.
9. The peptide of claim 8 , which is
10. The process of making
by reacting
with H-Tyr(tBu)-NH2.
11. The process of claim 10 , wherein Fomc-
is produced by solid phase synthesis comprising coupling a protected designated amino acid to a growing peptide chain covalently linked to an insoluble solid resin support to give Fomc-
12. A protected side chain peptide of formula (IV)
wherein P1 and P2 are protecting groups.
13. The peptide of claim 12 , which is
14. The process of making
comprising coupling a protected designated amino acid to a growing peptide chain covalently linked to an insoluble solid resin support to give
15. A protected side chain peptide of formula (VI)
wherein P1 and P2 are protecting groups.
16. The peptide of claim 15 , which is
17. The process of making
comprising coupling a protected designated amino acid to a growing peptide chain covalently linked to an insoluble solid resin support to give
and a deprotecting step.
20. The process of making
comprising coupling a protected designated amino acid to a growing peptide chain covalently linked to an insoluble solid resin support and selectively deprotecting the cysteine residues and forming an intramolecular disulfide bond between cysteine residues on the peptide chain before cleaving the peptide chain from the solid support to produce
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/553,567 US20100081788A1 (en) | 2008-09-03 | 2009-09-03 | Process for the Preparation of Pramlintide |
US13/113,354 US20110288235A1 (en) | 2008-09-03 | 2011-05-23 | Process for the Preparation of Pramlintide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19092808P | 2008-09-03 | 2008-09-03 | |
US12/553,567 US20100081788A1 (en) | 2008-09-03 | 2009-09-03 | Process for the Preparation of Pramlintide |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/113,354 Continuation-In-Part US20110288235A1 (en) | 2008-09-03 | 2011-05-23 | Process for the Preparation of Pramlintide |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100081788A1 true US20100081788A1 (en) | 2010-04-01 |
Family
ID=41726391
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/553,567 Abandoned US20100081788A1 (en) | 2008-09-03 | 2009-09-03 | Process for the Preparation of Pramlintide |
US12/553,482 Expired - Fee Related US8252896B2 (en) | 2008-09-03 | 2009-09-03 | Process for making bivalirudin |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/553,482 Expired - Fee Related US8252896B2 (en) | 2008-09-03 | 2009-09-03 | Process for making bivalirudin |
Country Status (11)
Country | Link |
---|---|
US (2) | US20100081788A1 (en) |
EP (2) | EP2349307B1 (en) |
JP (2) | JP2012502045A (en) |
KR (2) | KR20110056536A (en) |
CN (2) | CN102164609A (en) |
AR (2) | AR073544A1 (en) |
AU (2) | AU2009288036A1 (en) |
CA (2) | CA2736113A1 (en) |
IL (2) | IL211556A0 (en) |
TW (2) | TW201024316A (en) |
WO (2) | WO2010028122A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100249370A1 (en) * | 2007-06-29 | 2010-09-30 | Lonza Ag | Process for the production of pramlintide |
CN102180943A (en) * | 2010-12-16 | 2011-09-14 | 深圳市健元医药科技有限公司 | Production process of polypeptide medicament for assisting to reduce blood sugar |
CN104861045A (en) * | 2014-02-20 | 2015-08-26 | 复旦大学 | Cyclopeptide compound GG6F and preparation method thereof |
USRE46830E1 (en) | 2004-10-19 | 2018-05-08 | Polypeptide Laboratories Holding (Ppl) Ab | Method for solid phase peptide synthesis |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010075983A1 (en) | 2008-12-29 | 2010-07-08 | Lonza Braine Sa | Process for the production of bivalirudin |
WO2013042129A1 (en) * | 2011-09-23 | 2013-03-28 | Natco Pharma Limited | Improved process for preparation of bivalirudin |
WO2014032257A1 (en) * | 2012-08-30 | 2014-03-06 | 深圳翰宇药业股份有限公司 | Method for preparing bivalirudin |
SG11201506885UA (en) | 2013-03-21 | 2015-09-29 | Sanofi Aventis Deutschland | Synthesis of cyclic imide containing peptide products |
AU2014234400B2 (en) | 2013-03-21 | 2017-11-16 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
CN111499719B (en) * | 2020-03-19 | 2022-04-08 | 杭州固拓生物科技有限公司 | Method for synthesizing pramlintide |
CN118530332A (en) * | 2024-07-26 | 2024-08-23 | 南京羚诺生物医药技术研究院有限公司 | Preparation method of pramlintide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998367A (en) * | 1991-03-08 | 1999-12-07 | Amylin Corporation | Pramlintide pro H-amylin salts and compositions |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196404B1 (en) | 1989-08-18 | 1996-09-10 | Biogen Inc | Inhibitors of thrombin |
US5240913A (en) | 1989-08-18 | 1993-08-31 | Biogen, Inc. | Inhibitors of thrombin |
WO1992015317A1 (en) | 1991-03-08 | 1992-09-17 | Amylin Pharmaceuticals, Inc. | Synthetic preparation of amylin and amylin analogues |
GB9708918D0 (en) | 1997-05-01 | 1997-06-25 | Ppl Therapeutics Scotland Ltd | Methods |
US6821954B2 (en) * | 1997-09-18 | 2004-11-23 | Auckland Uniservices Limited | Compounds and uses thereof in treating bone disorders |
JP4602547B2 (en) * | 1998-03-23 | 2010-12-22 | トリメリス,インコーポレーテッド | Methods and compositions for peptide synthesis |
ATE480561T1 (en) | 2004-10-19 | 2010-09-15 | Lonza Ag | METHOD FOR SOLID PHASE PEPTIDE SYNTHESIS |
JP2008529969A (en) * | 2004-10-26 | 2008-08-07 | ロンザ ア−ゲ− | S-alkyl-sulfenyl protecting group in solid phase synthesis |
CA2618494A1 (en) * | 2005-09-14 | 2007-03-22 | Novetide, Ltd. | Process for production of bivalirudin |
US20070213505A1 (en) * | 2006-03-08 | 2007-09-13 | David Epstein | Solution Synthesis of Peptide Cell Growth Stimulators |
CN101033249B (en) | 2006-03-10 | 2011-05-11 | 周逸明 | Preparation method of synthesizing bivalirudin from solid phase polypeptide |
WO2008109079A2 (en) | 2007-03-01 | 2008-09-12 | Novetide, Ltd. | High purity peptides |
JP2010531828A (en) * | 2007-06-29 | 2010-09-30 | ロンザ アーゲー | Method for producing plumlintide |
US20090062511A1 (en) | 2007-09-05 | 2009-03-05 | Raghavendracharyulu Venkata Palle | Process for the preparation of bivalirudin and its pharmaceutical compositions |
WO2010075983A1 (en) * | 2008-12-29 | 2010-07-08 | Lonza Braine Sa | Process for the production of bivalirudin |
-
2009
- 2009-09-03 JP JP2011526194A patent/JP2012502045A/en active Pending
- 2009-09-03 TW TW098129667A patent/TW201024316A/en unknown
- 2009-09-03 US US12/553,567 patent/US20100081788A1/en not_active Abandoned
- 2009-09-03 EP EP09812204.7A patent/EP2349307B1/en not_active Not-in-force
- 2009-09-03 KR KR1020117007671A patent/KR20110056536A/en not_active Application Discontinuation
- 2009-09-03 TW TW098129702A patent/TWI395752B/en not_active IP Right Cessation
- 2009-09-03 EP EP09812207A patent/EP2334314A4/en not_active Withdrawn
- 2009-09-03 AR ARP090103394A patent/AR073544A1/en unknown
- 2009-09-03 WO PCT/US2009/055853 patent/WO2010028122A1/en active Application Filing
- 2009-09-03 CN CN2009801379027A patent/CN102164609A/en active Pending
- 2009-09-03 KR KR1020117007669A patent/KR101634830B1/en active IP Right Grant
- 2009-09-03 CA CA2736113A patent/CA2736113A1/en not_active Abandoned
- 2009-09-03 CA CA2736126A patent/CA2736126C/en not_active Expired - Fee Related
- 2009-09-03 WO PCT/US2009/055867 patent/WO2010028131A1/en active Application Filing
- 2009-09-03 AR ARP090103393A patent/AR073360A1/en unknown
- 2009-09-03 JP JP2011526190A patent/JP5788321B2/en not_active Expired - Fee Related
- 2009-09-03 CN CN2009801378950A patent/CN102164608A/en active Pending
- 2009-09-03 US US12/553,482 patent/US8252896B2/en not_active Expired - Fee Related
- 2009-09-03 AU AU2009288036A patent/AU2009288036A1/en not_active Abandoned
- 2009-09-03 AU AU2009288027A patent/AU2009288027B2/en not_active Ceased
-
2011
- 2011-03-03 IL IL211556A patent/IL211556A0/en unknown
- 2011-03-03 IL IL211555A patent/IL211555A/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998367A (en) * | 1991-03-08 | 1999-12-07 | Amylin Corporation | Pramlintide pro H-amylin salts and compositions |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46830E1 (en) | 2004-10-19 | 2018-05-08 | Polypeptide Laboratories Holding (Ppl) Ab | Method for solid phase peptide synthesis |
US20100249370A1 (en) * | 2007-06-29 | 2010-09-30 | Lonza Ag | Process for the production of pramlintide |
CN102180943A (en) * | 2010-12-16 | 2011-09-14 | 深圳市健元医药科技有限公司 | Production process of polypeptide medicament for assisting to reduce blood sugar |
CN104861045A (en) * | 2014-02-20 | 2015-08-26 | 复旦大学 | Cyclopeptide compound GG6F and preparation method thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100081788A1 (en) | Process for the Preparation of Pramlintide | |
US7348404B2 (en) | Solid-phase peptide synthesis and agent for use in such synthesis | |
US20220135639A1 (en) | Process for preparing a gip/glp1 dual agonist | |
US20100249370A1 (en) | Process for the production of pramlintide | |
US20110288235A1 (en) | Process for the Preparation of Pramlintide | |
US20220153804A1 (en) | Process of preparation of glucagon-like peptide-1 (glp-1) receptor agonists and their analogs | |
WO2021070202A1 (en) | A method for preparing glp-1 analogue by solid-phase peptide synthesis | |
US20220324936A1 (en) | Process for the manufacture of glucagon | |
JP2012525348A (en) | Insulin secretion-promoting peptide synthesis using solid phase and solution phase combination techniques | |
CN105408344B (en) | Peptide-resin conjugates and uses thereof | |
EP4436991A1 (en) | Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof | |
US20240116980A1 (en) | Compound or salt thereof and preparation method and application of same | |
US20100137561A1 (en) | Process for preparing therapeutic peptide | |
WO2020047994A1 (en) | Solid-phase synthesis method of abaloparatide | |
US20220033440A1 (en) | An improved process for the preparation of plecanatide | |
US9150615B2 (en) | Process for the preparation of leuprolide and its pharmaceutically acceptable salts | |
US7176282B1 (en) | Solid-phase peptide synthesis and agent for use in such synthesis | |
EP3398959B1 (en) | Method for preparing lixisenatide | |
CN107556363B (en) | Peptide or salt thereof and process for producing the same | |
US20230242581A1 (en) | Synthesis of a guanylate cyclase agonist by fragments based approach | |
US20230406900A1 (en) | Process for preparing glucagon-like peptide-1 | |
TW202348620A (en) | Process for preparing glucagon-like peptide-1 | |
WO2011095989A2 (en) | An improved process for the preparation of enfuvirtide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SCINOPHARM TAIWAN LTD.,TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HSIAO, TSUNG YU;DING, JIN GUO;SIGNING DATES FROM 20090901 TO 20090904;REEL/FRAME:023589/0537 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |